GAROFALO HEALTH CARE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.74 EUR | +0.42% |
|
+0.42% | +2.16% |
| Mar. 14 | GHC, revenues up but profit falls after Aurelia acquisition | AN |
| Mar. 14 | Garofalo Health Care S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 300.1 | 471.5 | 433.4 | 491.1 | 327.4 | 419.9 | 419.9 | - |
| Enterprise Value (EV) 1 | 252.8 | 566.2 | 531.1 | 633.5 | 472.4 | 411 | 598.9 | 560.9 |
| P/E ratio | 21.5 x | 36 x | 37.9 x | 26.2 x | 15.3 x | 25.8 x | 16.5 x | 15.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.93 x | 2.4 x | 2.06 x | 1.73 x | 1.01 x | 1.11 x | 0.91 x | 0.89 x |
| EV / Revenue | 1.62 x | 2.88 x | 2.52 x | 2.23 x | 1.46 x | 1.11 x | 1.29 x | 1.19 x |
| EV / EBITDA | 8.48 x | 14.8 x | 15.6 x | 11.9 x | 8.06 x | 6.13 x | 7.49 x | 6.84 x |
| EV / FCF | 26,961,715 x | -4,718,220 x | 123,079,339 x | 54,397,819 x | 16,345,684 x | - | 22,016,846 x | 14,759,427 x |
| FCF Yield | 0% | -0% | 0% | 0% | 0% | - | 0% | 0% |
| Price to Book | 1.68 x | 3.33 x | 2.34 x | 1.88 x | 1.17 x | 1.39 x | 1.32 x | 1.22 x |
| Nbr of stocks (in thousands) | 82,000 | 81,859 | 81,773 | 89,298 | 88,966 | 88,578 | 88,578 | - |
| Reference price 2 | 3.660 | 5.760 | 5.300 | 5.500 | 3.680 | 4.740 | 4.740 | 4.740 |
| Announcement Date | 4/18/19 | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 155.6 | 196.5 | 210.8 | 283.7 | 322.6 | 368.7 | 463 | 472 |
| EBITDA 1 | 29.8 | 38.2 | 34 | 53.1 | 58.6 | 67.1 | 80 | 82 |
| EBIT 1 | 23.59 | 24 | 15.49 | 28.23 | 31.66 | 39.23 | 48 | 49 |
| Operating Margin | 15.16% | 12.21% | 7.35% | 9.95% | 9.82% | 10.64% | 10.37% | 10.38% |
| Earnings before Tax (EBT) 1 | 18.03 | 18.66 | 13.02 | 23.99 | 27.37 | 28.93 | 35 | 37 |
| Net income 1 | 13.58 | 13.14 | 11.78 | 18.83 | 21.43 | 20.8 | 25 | 27 |
| Net margin | 8.73% | 6.69% | 5.59% | 6.64% | 6.64% | 5.64% | 5.4% | 5.72% |
| EPS 2 | 0.1700 | 0.1600 | 0.1400 | 0.2100 | 0.2400 | 0.1800 | 0.2870 | 0.3040 |
| Free Cash Flow | 9.377 | -120 | 4.315 | 11.65 | 28.9 | - | 27.2 | 38 |
| FCF margin | 6.02% | -61.07% | 2.05% | 4.11% | 8.96% | - | 5.87% | 8.05% |
| FCF Conversion (EBITDA) | 31.47% | - | 12.69% | 21.93% | 49.32% | - | 34% | 46.34% |
| FCF Conversion (Net income) | 69.03% | - | 36.63% | 61.83% | 134.89% | - | 108.8% | 140.74% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/18/19 | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2020 S1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 92.86 | 89.9 | 73.09 | 133.5 | 64.38 | - | 80.41 | 85.88 | 166.3 | 70.28 | 86 | 92.28 | 94.38 | 186.7 | 76.47 | 93 |
| EBITDA 1 | 17.38 | 8.747 | 14.15 | 24.74 | 7.72 | - | 14.33 | 16.84 | 31.17 | 11.15 | 16.28 | 18.76 | 19.49 | 38.25 | 12.72 | 16 |
| EBIT 1 | 13.05 | 3.272 | - | - | 2.2 | - | 7.845 | 11.86 | 19.71 | 5.553 | 6.717 | 13.96 | 12.04 | 26.01 | 6.129 | 10 |
| Operating Margin | 14.06% | 3.64% | - | - | 3.42% | - | 9.76% | 13.82% | 11.85% | 7.9% | 7.81% | 15.13% | 12.76% | 13.93% | 8.02% | 10.75% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | 1.249 | 5.485 | 9.769 | - | 5.773 | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | 1.39% | 7.5% | 7.32% | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | 0.0200 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/26/19 | 9/23/20 | 9/13/21 | 9/13/21 | 11/14/22 | 3/16/22 | 5/13/22 | 9/12/22 | 9/12/22 | 11/14/22 | 3/16/23 | 5/15/23 | 9/12/23 | 9/12/23 | 11/14/23 | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 94.7 | 97.7 | 142 | 145 | 137 | 179 | 141 |
| Net Cash position 1 | 47.3 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 2.478 x | 2.873 x | 2.681 x | 2.475 x | 2.045 x | 2.238 x | 1.72 x |
| Free Cash Flow | 9.38 | -120 | 4.32 | 11.6 | 28.9 | - | 27.2 | 38 |
| ROE (net income / shareholders' equity) | 9.91% | 6.96% | 5.96% | 8.13% | 7.94% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.180 | 1.730 | 2.260 | 2.920 | 3.140 | 3.400 | 3.600 | 3.900 |
| Cash Flow per Share | - | - | - | 0.4100 | 0.4900 | - | - | - |
| Capex | 9.14 | 8.81 | - | 24.7 | 15 | - | 18.5 | 18.9 |
| Capex / Sales | 5.87% | 4.48% | - | 8.7% | 4.64% | - | 4% | 4% |
| Announcement Date | 4/18/19 | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.74
EUR
Average target price
6.3
EUR
Spread / Average Target
+32.91%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.16% | 448M | |
| -20.16% | 16.21B | |
| +4.50% | 12.44B | |
| +3.98% | 11.58B | |
| +9.72% | 10.79B | |
| +23.61% | 8.26B | |
| -2.19% | 7.68B | |
| +20.75% | 7.2B | |
| +4.49% | 6.67B | |
| +50.89% | 4.66B |
- Stock Market
- Equities
- GHC Stock
- Financials Garofalo Health Care S.p.A.
